NCT03373903进行中（未招募）2 期
A Multicenter, Dose-finding Study to Determine if Oral BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in Elderly Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 652
- 试验地点
- 1
- 主要终点
- The percentage of subjects with 1 or more laboratory-confirmed RTIs through Week 16
研究概览
简要总结
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
详细描述
This is a randomized, blinded, placebo-controlled, multicenter, parallel-group, dose finding 24-week study to assess the safety, tolerability and efficacy of up to 3 doses of BEZ235 alone and in combination with RAD001 as compared to placebo in elderly subjects who are at increased risk of respiratory tract infection related-morbidity and mortality. The study will be composed of up to a 6-week screening and run-in period, a 16-week treatment period and an 8-week follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects
- •Age ≥ 85 years
- •Age ≥ 65 and < 85 years with one or more of the following conditions:
- •Chronic Obstructive Pulmonary Disease (COPD)
- •Chronic bronchitis
- •Type 2 Diabetes Mellitus (T2DM)
- •Congestive Heart Failure (CHF) New York Heart Association (NYHA) functional classification I-II
- •Current smoker
- •One or more emergency room visits or hospitalizations for a RTI during the previous 12 months
排除标准
- •Subjects with medically significant cardiac conditions including NYHA functional classification III-IV
- •Subjects with Type I diabetes mellitus.
- •Subjects with clinically significant underlying pulmonary disease other than asthma, GOLD Class I and II COPD or chronic bronchitis
- •History of malignancy in any organ system within the past 5 years except for the following:
- •Localized basal cell or squamous cell carcinoma of the skin, prostate cancer confined to the gland, cervical carcinoma in situ, breast cancer localized to the breast.
- •Subjects with any one of the following:
- •hemoglobin < 10.0 g/dL for males and < 9.0 for females
- •white blood cell (WBC) count < 3,500/mm3,
- •neutrophil count < 2,000/mm3
- •platelet count < 125,000/mm3
- •Subjects with a history of a systemic autoimmune disease or receiving immunosuppressive therapy
- •Recent surgery other than minor skin surgery
- •Liver disease or liver injury
- •History or presence of impaired renal function
- •History of immunodeficiency diseases
- •Subjects with active infection
- •Subjects with a Mini Mental Status Examination (MMSE) score <24 at screening.
- •Significant illness (based on the subject's medical history and the clinical judgement of the investigator) which has not resolved within two (2) weeks prior to initial dosing.
研究组 & 干预措施
BEZ235 plus RAD001 once daily for 16 weeks
Experimental
干预措施: BEZ235 plus everolimus (RAD001) (Drug)
Placebo once daily for 16 weeks
Placebo Comparator
干预措施: Placebo (Other)
BEZ235 once daily for 16 weeks
Experimental
干预措施: BEZ235 (Drug)
BEZ235 twice daily for 16 weeks
Experimental
干预措施: BEZ235 (Drug)
结局指标
主要结局
The percentage of subjects with 1 or more laboratory-confirmed RTIs through Week 16
时间窗: 16 weeks
次要结局
- The rate of RTIs/person through week 16(16 weeks)
- Peak Plasma Concentration (Cmax)(8 weeks)
- The percentage of subjects with 1 or more laboratory-confirmed RTIs through week 24(24 weeks)
- Percent of subjects who develop one or more RTIs through week 16(16 weeks)
- The rate of RTIs per person through week 24(24 weeks)
- Area under the plasma concentration versus time curve (AUC)(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid TumorsCancerNCT01508104University of Cincinnati19
撤回
1 期
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and NeutropeniaHematologic DiseasesFeverNeutropeniaCancerNCT00520325Enzon Pharmaceuticals, Inc.
已完成
1 期
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabMetastatic or Locally Advanced Solid TumorsNCT01285466Novartis Pharmaceuticals110
撤回
2 期
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaMalignant PEComa (Perivascular Epithelioid Cell Tumors)NCT01690871Novartis Pharmaceuticals
已完成
1 期
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabLocally Advance Breast Cancer (LABC)Metastatic Breast Cancer (MBC)NCT01471847Novartis Pharmaceuticals5